Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T06:20:41.865Z Has data issue: false hasContentIssue false
  • English
  • Français

Understanding depot antipsychotics: an illustrated guide to kinetics

Published online by Cambridge University Press:  18 December 2013

Jonathan M. Meyer
Jonathan M. Meyer*
Affiliation:
Patton State Hospital, Patton, California, USA; Mental Health Intensive Case Management, VA San Diego Healthcare System, San Diego, California, USA; Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, California, USA; Department of Psychiatry, Loma Linda University, Loma Linda, California, USA
*
*Address for correspondence: Jonathan M. Meyer, 3350 La Jolla Village Drive (116-A), San Diego, CA 92161, USA. (Email: jmmeyer@ucsd.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Long-acting injectable (LAI) antipsychotics can have considerable advantages over oral medications for the management of patients with schizophrenia. Despite the high prevalence of treatment nonadherence with oral pharmacotherapy, LAI antipsychotics are significantly underutilized in this patient population. The availability of newer LAI antipsychotic preparations combined with a resurgent interest in the use of typical antipsychotics has rekindled awareness of the value of LAI medications. This article is intended to provide a visual understanding of the various kinetic profiles of LAI antipsychotics to facilitate initiation and greater use of these agents.

Keywords

Antipsychoticdepotkineticslong-acting injectableschizophrenia
Type
CME Review Article
Information
CNS Spectrums , Volume 18 , Issue s1: CME SUPPLEMENT , December 2013 , pp. 55 - 68
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. The author would like to acknowledge the contributions of Michael A. Cummings, MD, Psychopharmacology Consultant, Psychopharmacology Resource Network—California Department of State Hospitals.

References

1.Kurland, AA, Richardson, JH. A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate. Psychopharmacologia. 1966; 9(4): 320–327.Google Scholar
2.Deberdt, R, Elens, P, Berghmans, W, etal. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand. 1980; 62(4): 356–363.Google Scholar
3.Robinson, D, Woerner, MG, Alvir, JM, etal. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3): 241–247.CrossRefGoogle ScholarPubMed
4.Agid, O, Foussias, G, Remington, G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010; 11(14): 2301–2317.Google Scholar
5.Leucht, C, Heres, S, Kane, JM, etal. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011; 127(1–3): 83–92.Google Scholar
6.Byerly, MJ, Thompson, A, Carmody, T, etal. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007; 58(6): 844–847.Google Scholar
7.Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment. 2005; 11(3): 203–211.Google Scholar
8.Hartling, L, Abou-Setta, AM, Dursun, S, etal. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(7): 498–511.Google Scholar
9.Lieberman, JA, Stroup, TS, McEvoy, JP, etal. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.Google Scholar
10.Jones, PB, Barnes, TRE, Davies, L, etal. Randomized controlled trial of the effect on Quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63(10): 1079–1087.Google Scholar
11.Tiihonen, J, Haukka, J, Taylor, M, etal. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. [Erratum appears in Am J Psychiatry. 2012;169(2):223]. Am J Psychiatry. 2011; 168(6): 603–609.Google Scholar
12.Ereshefsky, L, Mascarenas, CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003; 64(Suppl 16): 18–23.Google Scholar
13.Ereshefsky, L, Saklad, SR, Jann, MW, etal. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry. 1984; 45(5 Pt 2): 50–59.Google ScholarPubMed
14.Glazer, WM. Fluphenazine decanoate: its steady-state pharmacologic profile and relationship to tardive dyskinesia. Schizophr Res. 1988; 1(6): 425–429.Google Scholar
15.Wistedt, B. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. Int Clin Psychopharmacol. 1986; 1(Suppl 1): 15–23.Google Scholar
16.Gitlin, MJ, Nuechterlein, KH, Mintz, J, etal. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression. Psychopharmacology. 2000; 148(4): 350–354.CrossRefGoogle ScholarPubMed
17.Marder, SR, Aravagiri, M, Wirshing, WC, etal. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002; 53(1–2): 25–30.CrossRefGoogle ScholarPubMed
18.Midha, KK, Hubbard, JW, Marder, SR, Marshall, BD, Van Putten, T. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci. 1994; 19(4): 254–264.Google Scholar
19.Zhou, SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009; 48(12): 761–804.Google Scholar
20.Besag, FM, Berry, D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006; 29(2): 95–118.Google Scholar
21.Simpson, GM, Kunz-Bartholini, E. Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst. 1968; 29(4): 269–274.Google Scholar
22.Iyo, M, Tadokoro, S, Kanahara, N, etal. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013; 33(3): 398–404.Google Scholar
23.Jann, MW, Ereshefsky, L, Saklad, SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985; 10(4): 315–333.Google Scholar
24.Covell, NH, McEvoy, JP, Schooler, NR, etal. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012; 73(5): 669–675.Google Scholar
25.Meyer, JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010; 4: 23–42.Google Scholar
26.Marder, SR, Midha, KK, Van Putten, T, etal. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry. 1991; 158(5): 658–665.Google Scholar
27.Spanarello, S, La Ferla, T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. In press.Google Scholar
28.Ereshefsky, L, Toney, G, Saklad, SR, Anderson, C, Seidel, D. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry. 1993; 44(12): 1155–1161.Google Scholar
29.Wei, FC, Jann, MW, Lin, HN, Piao-Chien, C, Chang, WH. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry. 1996; 57(7): 298–302.Google Scholar
30.Selmin, F, Blasi, P, DeLuca, PP. Accelerated polymer biodegradation of risperidone poly(D,L-lactide-co-glycolide) microspheres. AAPS PharmSciTech. 2012; 13(4): 1465–1472.CrossRefGoogle ScholarPubMed
31.Harrison, TS, Goa, KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004; 18(2): 113–132.Google Scholar
32.Janssen Pharmaceuticals Inc. Risperdal Consta package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012.Google Scholar
33.Chue, P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007; 3(1): 13–39.Google Scholar
34.Turner, M, Eerdekens, E, Jacko, M, Eerdekens, M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacology. 2004; 19(4): 241–249.Google Scholar
35.Linnet, K, Ejsing, TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008; 18(3): 157–169.Google Scholar
36.De Leon, J, Wynn, G, Sandson, NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010; 51(1): 80–88.Google Scholar
37.Wilson, WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract. 2004; 10(6): 393–401.CrossRefGoogle ScholarPubMed
38.Meyer, JM. Drug-drug interactions with antipsychotics. CNS Spectr. 2007; 12(Suppl 21): 6–9.Google Scholar
39.Samtani, MN, Vermeulen, A, Stuyckens, K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009; 48(9): 585–600.CrossRefGoogle ScholarPubMed
40.Panagiotidis, G, Arthur, HW, Lindh, JD, Dahl, M-L, Sjoqvist, F. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit. 2007; 29(4): 417–422.CrossRefGoogle ScholarPubMed
41.Hendset, M, Molden, E, Refsum, H, Hermann, M. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009; 29(6): 537–541.Google Scholar
42.Pandina, GJ, Lindenmayer, J-P, Lull, J, etal. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. .[Erratum appears in J Clin Psychopharmacol. 2010;30(4):364]. J Clin Psychopharmacol. 2010; 30(3): 235–244.Google Scholar
43.Janssen Pharmaceuticals Inc. Invega Sustenna package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012.Google Scholar
44.Hough, D, Gopal, S, Vijapurkar, U, etal. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010; 116(2–3): 107–117.Google Scholar
45.Mamo, D, Kapur, S, Keshavan, M, etal. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008; 33(2): 298–304.Google Scholar
46.Frampton, JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs. 2010; 70(17): 2289–2313.Google Scholar
47.Detke, HC, Zhao, F, Garhyan, P, Carlson, J, McDonnell, D. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011; 26(1): 35–42.CrossRefGoogle ScholarPubMed
48.Detke, HC, McDonnell, DP, Brunner, E, etal. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010; 10: 43.Google Scholar
49.McDonnell, DP, Detke, HC, Bergstrom, RF, etal. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010; 10: 45.Google Scholar
50. U.S. FDA. FDA Drug Safety Podcast: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm357659.htm. Accessed June 28, 2013.Google Scholar
51.Eli Lilly and Company. Relprevv package insert. Indianapolis, IN: Lilly USA, LLC; 2011.Google Scholar
52.Kane, JM, Sanchez, R, Perry, PP, etal. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617–624.Google Scholar
53.Fleischhacker, WW, Sanchez, R, Johnson, B, etal. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013; 28(4): 171–176.Google Scholar
54.Mallikaarjun, S, Kane, JM, Bricmont, P, etal. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia Research. 2013; 150(1): 281–288.Google Scholar
55.Burris, KD, Molski, TF, Xu, C, etal. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002; 302(1): 381–389.Google Scholar
56.Otsuka Pharmaceutical Co. Ltd. Maintena package insert. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2013.Google Scholar
57.Sparshatt, A, Taylor, D, Patel, MX, Kapur, S. A systematic review of aripiprazole—dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1556.Google Scholar
58.Letmaier, M, Painold, A, Holl, AK, Grohmann, R, Vergin, H. Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. Int J Psychiatry Clin Pract. 2012; 16(2): 153–156.Google Scholar